Standard BioTools (NASDAQ:LAB) versus SQI Diagnostics (OTCMKTS:SQIDF) Head-To-Head Analysis

SQI Diagnostics (OTCMKTS:SQIDF) and Standard BioTools (NASDAQ:LAB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

53.7% of Standard BioTools shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQI Diagnostics and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQI Diagnostics	N/A	N/A	N/A
Standard BioTools	100.36%	-7.57%	-6.14%

Valuation & Earnings

This table compares SQI Diagnostics and Standard BioTools”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQI Diagnostics	N/A	N/A	N/A	N/A	N/A
Standard BioTools	$84.60 million	3.03	-$74.90 million	$0.22	2.97

SQI Diagnostics has higher earnings, but lower revenue than Standard BioTools.

Analyst Ratings

This is a summary of current ratings and target prices for SQI Diagnostics and Standard BioTools, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQI Diagnostics	0	0	0	0	0.00
Standard BioTools	1	2	0	0	1.67

Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 106.74%. Given Standard BioTools’ stronger consensus rating and higher possible upside, analysts plainly believe Standard BioTools is more favorable than SQI Diagnostics.

Summary

Standard BioTools beats SQI Diagnostics on 6 of the 8 factors compared between the two stocks.

About SQI Diagnostics

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.